Binge Eating Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Binge Eating Disorder (US)
Binge eating disorder (BED) is a prevalent condition in the United States, affecting millions of individuals across diverse demographics. It is characterized by recurrent episodes of excessive food consumption accompanied by a lack of control over eating behavior, leading to significant emotional and physical distress. Effective treatment often involves a combination of psychotherapy, such as CBT, and medications such as lisdexamfetamine and antidepressants. However, BED remains underdiagnosed due to stigma and low awareness. Addressing these challenges through public education and healthcare training can improve diagnosis and treatment outcomes, while ongoing research may lead to more effective therapies in the future. In this report, we assess drug usage patterns in BED based on U.S. patient-level claims data.
Questions answered
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed BED patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed BED patients?
- How has lisdexamfetamine (Vyvanse; generics) been integrated into the treatment algorithm, and what is its source of business?
- What percentage of BED patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of BED patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Key drugs covered
bupropion, lisdexamfetamine (Vyvanse; generics), semaglutide, SSRIs, topiramate
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:
- Understand patient flow between lines of therapy.
- Evaluate your brand share against competitors.
- Accurately assess your source of business.
- Quantify opportunities at different stages of the treatment algorithm.
Key features
Dashboard featuring interactive visuals, easy navigation, and expanded analyses.
Real-world data
Longitudinal patient-level claims data analysis
Key analyses
- Brand / therapy usage across longitudinal patient sample
- Newly diagnosed patient analysis
- Treatment initiation and progression
- Line of therapy analysis
- Combination therapy analysis
- Source of business for recently treated patients
- Persistency and compliance analysis
- Product-level patient flow charts
